Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Cavassini

Showing results (41-50 of 75) with videos related to

Pageof 8
Sort By:
HIV Medicine|March 20, 2014
The rate of recovery in renal function when patients with HIV infection discontinue treatment with tenofovirJ Young, Q Wang, C A Fux, et al.
Zoonoses and Public Health|February 7, 2014
Seroprevalence of hepatitis E virus in domestic pigs and wild boars in SwitzerlandC Burri, F Vial, M-P Ryser-Degiorgis, et al.
HIV Medicine|May 8, 2008
Androgen and gonadotropin patterns differ in HIV-1-infected men who develop lipoatrophy during antiretroviral therapy: a case-control studyD M Wunder, C A Fux, N A Bersinger, et al.
HIV Medicine|September 25, 2012
Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort StudyR Weber, M Ruppik, M Rickenbach, et al.
HIV Medicine|January 22, 2011
Clinical relevance of cytomegalovirus viraemia(*,†)E Boffi El Amari, C Combescure, S Yerly, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|April 1, 2009
A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: Raltegravir, maraviroc, darunavir, and etravirineA Fayet, A Béguin, B Zanolari, et al.
British Journal of Cancer|July 31, 2008
Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapyS Franceschi, L Dal Maso, M Rickenbach, et al.
HIV Medicine|August 15, 2006
Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort StudyT R Glass, C Ungsedhapand, M Wolbers, et al.
Clinical Pharmacology and Therapeutics|January 20, 2007
Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individualsM Rotger, H Tegude, S Colombo, et al.
Clinical Pharmacology and Therapeutics|February 20, 2009
Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individualsM Arab-Alameddine, J Di Iulio, T Buclin, et al.
Pageof 8

Showing results (41-50 of 75) with videos related to

Sort By:
Pageof 8
HIV Medicine|March 20, 2014
The rate of recovery in renal function when patients with HIV infection discontinue treatment with tenofovirJ Young, Q Wang, C A Fux, et al.
Zoonoses and Public Health|February 7, 2014
Seroprevalence of hepatitis E virus in domestic pigs and wild boars in SwitzerlandC Burri, F Vial, M-P Ryser-Degiorgis, et al.
HIV Medicine|May 8, 2008
Androgen and gonadotropin patterns differ in HIV-1-infected men who develop lipoatrophy during antiretroviral therapy: a case-control studyD M Wunder, C A Fux, N A Bersinger, et al.
HIV Medicine|September 25, 2012
Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort StudyR Weber, M Ruppik, M Rickenbach, et al.
HIV Medicine|January 22, 2011
Clinical relevance of cytomegalovirus viraemia(*,†)E Boffi El Amari, C Combescure, S Yerly, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|April 1, 2009
A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: Raltegravir, maraviroc, darunavir, and etravirineA Fayet, A Béguin, B Zanolari, et al.
British Journal of Cancer|July 31, 2008
Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapyS Franceschi, L Dal Maso, M Rickenbach, et al.
HIV Medicine|August 15, 2006
Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort StudyT R Glass, C Ungsedhapand, M Wolbers, et al.
Clinical Pharmacology and Therapeutics|January 20, 2007
Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individualsM Rotger, H Tegude, S Colombo, et al.
Clinical Pharmacology and Therapeutics|February 20, 2009
Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individualsM Arab-Alameddine, J Di Iulio, T Buclin, et al.
Pageof 8